Novo Nordisk A/s

Argos Therapeutics, Inc.

Centre National De La Recherche Scientifique

Birgitte Friedrichsen

Henrik Sune Andersen

Kristian Kjaergaard

Soeren Padkjaer

Berit Olsen Krogh

Petrus Johannes Louis Spee

Susanne Nedergaard Grell

Jens Buchardt

Peder Lisby Noerby

Soren Berg Padkjaer

Inger Lund Pedersen

Mette Dahl Andersen

Albrecht Gruhler

Jesper Kastrup

Lars Anders Svensson

Katarina Haakansson

Lars Hornum

Dorrit Baunsgaard

Peter Andreas Nicolai Reumert Wagtmann

Stefan Zahn

Elisabeth Douglas Galsgaard

Véronique Braud

Søren Berg Padkær

Inga Sig Nielsen Nørby

Jan Fleckner

Søren PADKJÆR

The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.

Antagonistic DR3 ligands

The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.

The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.

LLT-1 antibodies with new functional properties

The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1-and CD161-expressing cells play a role in disease pathogenesis.

The present invention provides humanized anti-human IFN-&#x3b1; monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.

Humanized antibodies against human interferon-alpha

Soluble versions of heterodimeric receptors, e.g., CD94/NKG2 receptors, and methods of producing and using such constructs, are described. The constructs comprise soluble fragments of, each receptor monomer, and some constructs further comprise at least one immunoglobulin Fc domain. Exemplary constructs are those wherein (1) each soluble fragment is linked to an immunoglobulin Fc domain, which are then allowed to dimerize, (2) each soluble fragment is linked to an immunoglobulin Fc domain mutated to promote forced dimerization with the correct counterpart, and (3) single-chain constructs where the monomeric receptor fragments are linked, and the C-terminal fragment is linked to an Fc domain.

Soluble heterodimeric CD94/NKG2 receptors fusion proteins

Growing community of inventors

Gentofte, Denmark

Birgitte Friedrichsen